PENCICLOVIR

/static/temp/default.svg Search structure
Trade Names
Synonyms
Status
Molecule Category UNKNOWN
ATC D06BB06 J05AB13
UNII 359HUE8FJC
EPA CompTox DTXSID9046491

Structure

InChI Key JNTOCHDNEULJHD-UHFFFAOYSA-N
Smiles Nc1nc(O)c2ncn(CCC(CO)CO)c2n1
InChI
InChI=1S/C10H15N5O3/c11-10-13-8-7(9(18)14-10)12-5-15(8)2-1-6(3-16)4-17/h5-6,16-17H,1-4H2,(H3,11,13,14,18)

Physicochemical Descriptors

Property Name Value
Molecular Formula C10H15N5O3
Molecular Weight 253.26
AlogP -0.9
Hydrogen Bond Acceptor 8.0
Hydrogen Bond Donor 4.0
Number of Rotational Bond 5.0
Polar Surface Area 130.31
Molecular species NEUTRAL
Aromatic Rings 2.0
Heavy Atoms 18.0

Bioactivity

Mechanism of Action Action Reference
Human herpesvirus 1 DNA polymerase inhibitor INHIBITOR DailyMed
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Transferase
- 11000 - - 0
Assay Description Organism Bioactivity Reference
Inhibition of DNA polymerase None 0.0 %
Inhibition of DNA polymerase None 8.0 %
Concentration required to reduce the viral DNA in infected cells to 50% of untreated infected controls of Hepatitis B virus in primary duck hepatocyte (DHBV) cultures. Anas sp. 0.3 ug.mL-1
In vitro antiviral activity against duck hepatitis B virus (DHBV) Hepatitis B virus 700.0 nM
Concentration required to reduce the viral DNA in infected cells to 50% of untreated infected controls. Duck hepatitis B virus 0.3 ug.mL-1
Tested for Antiherpetic activity against VZV from Kawaguchi strain in HEL cell lines. Homo sapiens 5.6 ug.mL-1
Tested for Antiherpetic activity against VZV from clinical isolates of HEL cell lines.(average of 11 isolates) Homo sapiens 10.0 ug.mL-1
Effective concentration necessary to decrease extracellular Hepatitis B virus DNA levels by 50% in human hepatoblastoma cell line (2.2.15 cells) in vitro Homo sapiens 190.0 nM
Tested for Antiherpetic activity against HSV-1 from Tomioka strain in MRC-5 cell lines. Homo sapiens 0.54 ug.mL-1
Tested for Antiherpetic activity against HSV-2 from 186 strain in MRC-5 cell lines. Homo sapiens 1.2 ug.mL-1
The effective concentration to show 50% of activity was measured on varicella zoster virus(VZV) cell culture Human herpesvirus 3 140.0 nM
Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect Human herpesvirus 1 strain KOS 500.0 nM
Antiviral activity against Herpes simplex virus 2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect Human herpesvirus 2 strain G 600.0 nM
Antiviral activity against Varicella-Zoster virus OKA infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect Human herpesvirus 3 strain Oka vaccine 620.0 nM
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 2 to 3 days post-infection Human herpesvirus 1 strain KOS 480.0 nM
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 2 to 3 days post-infection Human herpesvirus 2 strain G 840.0 nM
Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media, using NBS plates, by OD(600) Staphylococcus aureus subsp. aureus 6.12 %
Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by OD(600) Escherichia coli 2.89 %
Antibacterial activity against Klebsiella pneumoniae MDR ATCC 70063 (CO-ADD:GN_003); MIC in CAMBH media using NBS plates, by OD(600) Klebsiella pneumoniae 17.55 %
Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 (CO-ADD:GN_042); MIC in CAMBH media using NBS plates, by OD(600) Pseudomonas aeruginosa 16.28 %
Antibacterial activity against Acinetobacter baumannii ATCC 19606 (CO-ADD:GN_034); MIC in CAMBH media using NBS plates, by OD600 Acinetobacter baumannii 30.92 %
Antifungal activity against Candida albicans ATCC 90028 (CO-ADD:FG_001); MIC in YNB media using NBS plates, by OD630 Candida albicans 0.56 %
Antifungal activity against Cryptococcus neoformans H99 ATCC 208821 (CO-ADD:FG_002); MIC in YNB media using NBS plates, by Resazurin OD(600-570) Cryptococcus neoformans -9.17 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging Homo sapiens 1.54 %
Antiviral activity against herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity by microscopic analysis Human alphaherpesvirus 1 800.0 nM
Antiviral activity against herpes simplex virus 2 G infected in HEL cells assessed as reduction in virus-induced cytopathogenicity by microscopic analysis Human alphaherpesvirus 2 200.0 nM
Antiviral activity against thymidine kinase deficient and aciclovir resistant herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity by microscopic analysis Human alphaherpesvirus 1 200.0 nM
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 11.85 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.12 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.12 %

Related Entries

Cross References

Resources Reference
ChEBI 7956
ChEMBL CHEMBL1540
DrugBank DB00299
DrugCentral 2079
FDA SRS 359HUE8FJC
Human Metabolome Database HMDB0014444
KEGG C07417
PDB PE2
PharmGKB PA450839
PubChem 135398748
SureChEMBL SCHEMBL3494
ZINC ZINC000000001899
CONTENTS